biomea fusion
Thorsten received his chemistry training at the universities of Münster/Germany, Osaka/Japan and at Stanford University/USA. He has extensive experience leading teams to discover and develop small molecule drug candidates. He spent more than a decade at Gilead Sciences and contributed to the company’s drug portfolio and pipeline. With his team, he synthesized ledipasvir, a component of Harvoni®, to cure HCV infections. He led research to the discovery of GS-4875, a COT inhibitor in advanced clinical studies for the treatment of IBD. More recently at Terns Pharmaceuticals, his chemistry leadership provided multiple optimized candidates and identified TERN-501, a selective THR- b agonist for the treatment of NASH.
This person is not in any offices
biomea fusion
Biomea Fusion, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company was formed in 2017 by a small group of biotech executives that came together with the common goal of achieving better therapies for patients.